AAAAAA

   
Results: 1-12 |
Results: 12
RELEASE OF CYTOKINES AND SOLUBLE CELL-SURFACE MOLECULES BY PBMC AFTERACTIVATION WITH THE BISPECIFIC ANTIBODY CD3XCD19
Authors: KLEIN SC BOER LH DEWEGER RA DEGAST GC BAST EJEG
Citation: Sc. Klein et al., RELEASE OF CYTOKINES AND SOLUBLE CELL-SURFACE MOLECULES BY PBMC AFTERACTIVATION WITH THE BISPECIFIC ANTIBODY CD3XCD19, Scandinavian journal of immunology, 46(5), 1997, pp. 452-458
TARGETING OF CYTOTOXIC T-CELLS AGAINST LEUKEMIC B-CELLS BY BISPECIFICANTIBODY (ACD3 X ACD19) DOES NOT DISTRACT THE T-CELL FROM ITS PRIMARYTARGET
Authors: KLEIN SC VANDERBURG SH BOER LH MELIEF CJM KAST WM DEGAST GC BAST EJEG
Citation: Sc. Klein et al., TARGETING OF CYTOTOXIC T-CELLS AGAINST LEUKEMIC B-CELLS BY BISPECIFICANTIBODY (ACD3 X ACD19) DOES NOT DISTRACT THE T-CELL FROM ITS PRIMARYTARGET, The Journal of immunology, 159(11), 1997, pp. 5545-5549
EFFICACY AND TOXICITY OF PLASMA-CELL-REACTIVE MONOCLONAL-ANTIBODIES B-B2 AND B-B4 AND THEIR IMMUNOTOXINS
Authors: VOOIJS WC POST J WIJDENES J SCHUURMAN HJ BOLOGNESI A POLITO L STIRPE F BAST EJEG DEGAST GC
Citation: Wc. Vooijs et al., EFFICACY AND TOXICITY OF PLASMA-CELL-REACTIVE MONOCLONAL-ANTIBODIES B-B2 AND B-B4 AND THEIR IMMUNOTOXINS, Cancer immunology and immunotherapy, 42(6), 1996, pp. 319-328
EXPRESSION OF 2 INTERLEUKIN-4 MESSENGER-RNA ISOFORMS IN B-LYMPHOID-CELLS
Authors: KLEIN SC GOLVERDINGEN JG VANWICHEN DF BOUWENS AGM STUIJ I TILANUS MGJ BAST EJEG DEWEGER RA
Citation: Sc. Klein et al., EXPRESSION OF 2 INTERLEUKIN-4 MESSENGER-RNA ISOFORMS IN B-LYMPHOID-CELLS, Cellular immunology, 167(2), 1996, pp. 259-268
IMMUNOTOXIN AND CD3 CONTAINING BISPECIFIC ANTIBODY-DIRECTED AGAINST THE SAME ANTIGEN (SYNDECAN-I) ARE EQUALLY EFFECTIVE IN-VITRO AGAINST PLASMA-CELL LINES
Authors: VOOIJS WC POST J GLENNIE M WIJDENES J STIRPE F BAST EJEG DEGAST GC
Citation: Wc. Vooijs et al., IMMUNOTOXIN AND CD3 CONTAINING BISPECIFIC ANTIBODY-DIRECTED AGAINST THE SAME ANTIGEN (SYNDECAN-I) ARE EQUALLY EFFECTIVE IN-VITRO AGAINST PLASMA-CELL LINES, Blood, 88(10), 1996, pp. 3616-3616
TARGETING OF CYTOTOXIC T-CELLS AGAINST LEUKEMIC B-CELLS BY BISPECIFICANTIBODY (ACD3XACD19) DOES NOT DISTRACT THE T-CELL FROM ITS PRIMARY TARGET
Authors: KLEIN SC VANDERBURG SH BOER LH MELIEF CJM KAST WM DEGAST GC BAST EJEG
Citation: Sc. Klein et al., TARGETING OF CYTOTOXIC T-CELLS AGAINST LEUKEMIC B-CELLS BY BISPECIFICANTIBODY (ACD3XACD19) DOES NOT DISTRACT THE T-CELL FROM ITS PRIMARY TARGET, Blood, 88(10), 1996, pp. 340-340
EFFECT OF TARGET-CELL ANTIGEN DENSITY ON THE EFFICACY OF THE BISPECIFIC ANTIBODY ACD3XACD19
Authors: KLEIN SC HOOIJBERG E BOER LH HEKMAN A DEWEGER RA BAST EJEG DEGAST GC
Citation: Sc. Klein et al., EFFECT OF TARGET-CELL ANTIGEN DENSITY ON THE EFFICACY OF THE BISPECIFIC ANTIBODY ACD3XACD19, Blood, 88(10), 1996, pp. 341-341
ASSOCIATED AUTOIMMUNITY IN ADDISONS-DISEASE
Authors: ZELISSEN PMJ BAST EJEG CROUGHS RJM
Citation: Pmj. Zelissen et al., ASSOCIATED AUTOIMMUNITY IN ADDISONS-DISEASE, Journal of autoimmunity, 8(1), 1995, pp. 121-130
EVALUATION OF CD38 AS TARGET FOR IMMUNOTHERAPY IN MULTIPLE-MYELOMA
Authors: VOOIJS WC SCHUURMAN HJ BAST EJEG DEGAST GC
Citation: Wc. Vooijs et al., EVALUATION OF CD38 AS TARGET FOR IMMUNOTHERAPY IN MULTIPLE-MYELOMA, Blood, 85(8), 1995, pp. 2282-2283
FIRST RESULTS OF INTRAVENOUS APPLICATION OF BISPECIFIC ANTIBODY (CD3 CD19 SHR-1) TO PATIENTS WITH CD19 POSITIVE B-CELL MALIGNANCIES - A PHASE-1 STUDY/
Authors: VANHOUTEN AA HAAGEN IA CLARK M GEERARS A DELAU W BAST EJEG DEGAST GC
Citation: Aa. Vanhouten et al., FIRST RESULTS OF INTRAVENOUS APPLICATION OF BISPECIFIC ANTIBODY (CD3 CD19 SHR-1) TO PATIENTS WITH CD19 POSITIVE B-CELL MALIGNANCIES - A PHASE-1 STUDY/, Experimental hematology, 21(8), 1993, pp. 1120-1120
INVITRO AND INVIVO MEASUREMENT OF CELL-MEDIATED-IMMUNITY IN PATIENTS WITH HIV-1 INFECTION
Authors: BORLEFFS JCC SCHUURMAN HJ VREHEN HM VANSCHAIK M BAST EJEG
Citation: Jcc. Borleffs et al., INVITRO AND INVIVO MEASUREMENT OF CELL-MEDIATED-IMMUNITY IN PATIENTS WITH HIV-1 INFECTION, Scandinavian journal of immunology, 37(6), 1993, pp. 634-636
CYTOKINE RELEASE AFTER INTRAVENOUS ADMINISTRATION OF BISPECIFIC ANTIBODY (CD3 CD19, SHR-1) - A PHASE-I STUDY IN PATIENTS WITH CD19 POSITIVEB-CELL MALIGNANCIES/
Authors: VANHOUTEN AA HAAGEN IA CLARK M GEERARS A DELAU W VROOM TM BAST EJEG DEGAST GC
Citation: Aa. Vanhouten et al., CYTOKINE RELEASE AFTER INTRAVENOUS ADMINISTRATION OF BISPECIFIC ANTIBODY (CD3 CD19, SHR-1) - A PHASE-I STUDY IN PATIENTS WITH CD19 POSITIVEB-CELL MALIGNANCIES/, Blood, 82(10), 1993, pp. 10000580-10000580
Risultati: 1-12 |